Governor Baldacci Attends Ceremony to Celebrate the Opening of ImmuCell's Renovated Facility in Conjunction With the Company's 2007 Annual Meeting of Shareholders

PORTLAND, ME--(Marketwire - June 7, 2007) - ImmuCell Corporation (NASDAQ: ICCC) today announced the election of its Board of Directors as the only matter of business at its Annual Meeting of Shareholders.

Following the meeting, the Company held a ceremony to formally open its renovated and expanded facility. ImmuCell recently completed an investment of approximately $1,000,000 in facility modifications and approximately $500,000 in new equipment as part of the Company's effort to gain compliance with current Good Manufacturing Practices (cGMP) regulations to facilitate the development and sale of its products in the U.S. and foreign markets. ImmuCell acquired its building in 1993 anticipating this kind of expansion, if warranted by growth of the Company. The project was completed on time and on budget with credit to the Maine contractors hired by the Company to do the work.

This event was attended by Maine's Governor John Baldacci and by City Counselor and former Mayor of the City of Portland, Jim Cohen. Mr. Michael F. Brigham, President and CEO, introduced Governor Baldacci to the meeting explaining that the investment in cGMP compliance, in addition to other benefits, may help the Company meet regulatory requirements necessary to sell its products in foreign markets.

"I am pleased that ImmuCell is committed to enhancing their ability to compete in the global marketplace," said Governor Baldacci. "This expansion mirrors what we are doing on the State level, making strategic investments to grow our economy. I am confident that ImmuCell will be yet another shining example of what can be accomplished in Maine with a high quality workforce and product and smart investments for future growth."

City Counselor Cohen added, "ImmuCell is one of, if not the longest, operating biotech companies in Portland. ImmuCell provides high quality jobs for approximately thirty people in the City, and its recent investments demonstrate a long-term commitment to our region. ImmuCell is a key player in Portland's growing biotechnology cluster, and we wish the company great success as it works to expand market share nationally and globally."

ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at http://www.immucell.com.

Contact Information: Contact: Michael F. Brigham President and Chief Executive Officer (207) 878-2770 Ext. 3106